Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles Nature Medicine Year : 2023

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Elise Deluche
Thomas Filleron
Thomas Bachelot
Christelle Levy
Maki Kobayashi
Marta Jimenez
Celine Mahier
Veronique Diéras

Abstract

The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing ( n = 72, cohort 1), HER2-low ( n = 74, cohort 2) and HER2 non-expressing ( n = 40, cohort 3) metastatic breast cancer. In the full analysis set population ( n = 177), the confirmed objective response rate (primary endpoint) was 70.6% (95% confidence interval (CI) 58.3–81) in cohort 1, 37.5% (95% CI 26.4–49.7) in cohort 2 and 29.7% (95% CI 15.9–47) in cohort 3. The primary endpoint was met in cohorts 1 and 2. Secondary endpoints included safety. No new safety signals were observed. During treatment, HER2-expressing tumors ( n = 4) presented strong T-DXd staining. Conversely, HER2 immunohistochemistry 0 samples ( n = 3) presented no or very few T-DXd staining (Pearson correlation coefficient r = 0.75, P = 0.053). Among patients with HER2 immunohistochemistry 0 metastatic breast cancer, 5 of 14 (35.7%, 95% CI 12.8–64.9) with ERBB2 expression below the median presented a confirmed objective response as compared to 3 of 10 (30%, 95% CI 6.7–65.2) with ERBB2 expression above the median. Although HER2 expression is a determinant of T-DXd efficacy, our study suggests that additional mechanisms may also be involved. (ClinicalTrials.gov identifier NCT04132960 .)
Fichier principal
Vignette du fichier
s41591-023-02478-2.pdf (6.92 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

hal-04187928 , version 1 (25-08-2023)

Identifiers

Cite

Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, et al.. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine, 2023, 29 (8), pp.2110 - 2120. ⟨10.1038/s41591-023-02478-2⟩. ⟨hal-04187928⟩
126 View
22 Download

Altmetric

Share

Gmail Facebook X LinkedIn More